Glucagon-like peptide 1:a novel therapeutic strategy for Alzheimer's disease

( views:72, downloads:0 )
Author:
WANG Xiao-Hui()
YANG Wei()
QI Jin-Shun()
Journal Title:
ACTA PHYSIOLOGICA SINICA
Issue:
Volume 62, Issue 05, 2010
DOI:
Key Word:

Abstract:

  • [1]Goedert M.Tau protein and the neurofibrillary pathology of Alzheimer's disease.Trends Neurosci 1993; 16(11):460-465.
  • [2]Hardy J,Selkce DJ.The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics.Science 2002; 297(5580):353-356.
  • [3]Walsh DM,Klyubin I,Fadeeva JV,Cullen WK,Anwyl R,Wolfe MS,Rowan MJ,Selkoe DJ.Naturally secreted oligo-mers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.Nature 2002; 416(6880):535-539.
  • [4]Yoshiike Y,Chui DH,Akagi T,Tanaka N,Takashima A.Specific compositions of amyloid-beta peptides as the determinant of toxic beta-aggregation.J Biol Chem 2003; 278(26):23648-23655.
  • [5]Yan XZ,Qiao JT,Dou Y,Qiao ZD.Beta-amyloid peptide fragment 31-35 induces apoptosis in cultured cortical neurons.Neuroscience 1999; 92(1):177-184.
  • [6]Qi JS,Qiao JT.Amyloid beta-protein fragment 31-35 forms ion channels in membrane patches excised from rat hippocampal neurons.Neuroscience 2001; 105(4):845-852.
  • [7]Zhang JM,Wu MN,Qi JS,Qiao JT.Amyloid beta-protein fragment 31-35 suppresses long-term potentiation in hippocampal CA1 region of rats in vivo.Synapse 2006; 60(4):307-313.
  • [8]Zhang JF,Qi JS,Qiao JT.Protein kinase C mediates amyloid beta-protein fragment 31-35-induced suppression of hippocampal late-phase long-term potentiation in vivo.Neurobiol Learn Mem 2009; 91(3):226-234.
  • [9]Pan YF,Chen XR,Wu MN,Ma CG,Qi JS.Arginine vasopressin prevents against Abeta(25-35)-induced impairment of spatial learning and memory in rats.Horm Behav 2010; 57(4-5):448-454.
  • [10]Haan MN.Therapy Insight:type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease.Nat Clin Pract Neurol 2006; 2(3):159-166.
  • [11]Gotz J.Ittner LM,Lim YA.Common features between diabetes mellitus and Alzheimer's disease.Cell Mol Life Sci 2009; 66(8):1321-1325.
  • [12]Logroscino G,Kang JH,Grodstein F.Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years.BMJ 2004; 328(7439):548.
  • [13]de la Monte SM,Wands JR.Alzheimer's disease is type 3 diabetes-evidence reviewed.J Diabetes Sci Technol 2008; 2(6):1101-1113.
  • [14]Biessels GJ,Staekenborg S,Brunner E,Brayne C,Scheltens P.Risk of dementia in diabetes mellitus:a systematic review.Lancet Neurol 2006; 5(1):64-74.
  • [15]Janson J,Laedtke T,Parisi JE,O'Brien P,Petersen RC,Butler PC.Increased risk of type 2 diabetes in Alzheimer disease.Diabetes 2004; 53(2):474-481.
  • [16]Li L,Holscher C.Common pathological processes in Alzheimer disease and type 2 diabetes:a review.Brain Res Rev 2007; 56(2):384-402.
  • [17]Holscher C,Gengler S,Gault VA,Harriott P,Mallot HA.Soluble beta-amyloid[25-35]reversibly impairs hippocampal synaptic plasticity and spatial learning.Eur J Pharmacol 2007; 561(1-3):85-90.
  • [18]Gebre-Medhin S,Mulder H,Pekny M,Westermark G,Tornell J,Westermark P,Sundler F,Ahren B,Betsholtz C.Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide(amylin).Biochem Biophys Res Commun 1998; 250(2):271-277.
  • [19]Alonso AC,Zaidi T,Grundke-Iqbal I,Iqbal K.Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease.Proc Natl Acad Sci U S A 1994; 91(12):5562-5566.
  • [20]Kim B,Backus C,Oh S,Hayes JM,Feldman EL.Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes.Endocrinology 2009; 150(12):5294-5301.
  • [21]Miklossy J,Qing H,Radenovic A,Kis A,Vileno B,Laszlo F,Miller L,Martins RN,Waeber G,Mooser V,Bosman F,Khalili K,Darbinian N,McGeer PL.Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.Neurobiol Aging 2010; 31(9):1503-1515.
  • [22]Freude S,Plum L,Schnitker J,Leeser U,Udelhoven M,Krone W,Bruning JC,Schubert M.Peripheral hyperinsulinemia promotes tan phosphorylation in vivo.Diabetes 2005; 54(12):3343-3348.
  • [23]Wang JZ,Grundke-Iqbal I,Iqbal K.Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.Eur J Neurosci 2007; 25(1):59-68.
  • [24]Zierath JR,Krook A,Wallberg-Henriksson H.Insulin action and insulin resistance in human skeletal muscle.Diabetologia 2000; 43(7):821-835.
  • [25]Fletcher B,Gulanick M,Lamendola C.Risk factors for type 2 diabetes mellitus.J Cardiovasc Nurs 2002; 16(2):17-23.
  • [26]Lester-Coll N,Rivera EJ,Soscia SJ,Doiron K,Wands JR,de la Monte SM.Intracerebral streptozotocin model of type 3 diabetes:relevance to sporadic Alzheimer's disease.J Alzheimers Dis 2006; 9(1):13-33.
  • [27]Plaschke K,Kopitz J,Siegelin M,Schliebs R,Salkovic-Petrisic M,Riederer P,Hoyer S.Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice.J Alzheimers Dis 2010; 19(2):691-704.
  • [28]Xie L,Helmerhorst E,Taddei K,Plewright B,Van Bronswijk W,Martins R.Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor.J Neurosci 2002; 22(10):RC221.
  • [29]Zhao WQ,De Felice FG,Fernandez S,Chen H,Lambert MP,Quon MJ,Krafft GA,Klein WL.Amyloid beta oligomers induce impairment of neuronal insulin receptors.FASEB J 2008; 22(1):246-260.
  • [30]Schmid AW,Freir DB,Herron CE.Inhibition of LTP in vivo by beta-amyloid peptide in different conformational states.Brain Res 2008; 1197:135-142.
  • [31]Freir DB,Costello DA,Herron CE.A beta 25-35-induced depression of long-term potentiation in area CA1 in vivo and in vitro is attenuated by verapamil.J Neurophysiol 2003; 89(6):3061-3069.
  • [32]Gureviciene I,Ikonen S,Gurevicius K,Sarkaki A,van Groen T,Pussinen R,Ylinen A,Tanila H.Normal induction but accelerated decay of LTP in APP+PS1 transgenic mice.Neurobiol Dis 2004; 15(2):188-195.
  • [33]Reisi P,Babri S,Alaei H,Sharifi MR,Mohaddes G,Noorbakhsh SM,Lashgari R.Treadmill running improves long-term potentiation(LTP)defects in streptozotocin-induced diabetes at dentate gyrus in rats.Pathophysiology 2009; 17(1):33-38.
  • [34]Biessels GJ,Kamal A,Ramakers GM,Urban IJ,Spruijt BM,Erkelens DW,Gispen WH.Place learning and hippocampal synaptic plasticity in streptozotoein-induced diabetic rats.Diabetes 1996; 45(9):1259-1266.
  • [35]Kamal A,Biessels GJ,Urban IJ,Gispen WH.Hippocampal synaptic plasticity in streptozotocin-diabetic rats:impairment of long-term potentiation and facilitation of long-term depression.Neuroscience 1999; 90(3):737-745.
  • [36]Biessels GJ,Kamal A,Urban IJ,Spruijt BM,Erkelens DW,Gispen WH.Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats:effects of insulin treatment.Brain Res 1998; 800(1):125-135.
  • [37]Gault VA,Holscher C.GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid.Eur J Pharmacol 2008; 587(1-3):112-117.
  • [38]Sharma M,Gupta YK.Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment.Life Sci 2001; 68(9):1021-1029.
  • [39]Hoist JJ.The physiology of glucagon-like peptide 1.Physiol Rev 2007; 87(4):1409-1439.
  • [40]Timmers L,Henriques JP,de Kleijn DP,Devries JH,Kemperman H,Steendijk P,Vedaan CW,Kerver M,Piek JJ,Doevendans PA,Pasterkamp G,Hoefer IE.Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.J Am Coil Cardiol 2009; 53(6):501-510.
  • [41]Degn KB,Juhl CB,Sturis J,Jakobsen G,Brock B,Chandramouli V,Rungby J,Landau BR,Schmitz O.One week's treatment with the long-acting glucagon-like peptide 1 derivative iiraglutide(NN2211)markedly improves 24-h glycemia and alpha-and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.Diabetes 2004; 53(5):1187-1194.
  • [42]Nagakura T,Yasuda N,Yamazaki K,Ilmta H,Yoshikawa S,Asano O,Tanaka I.Improved glucose tolerance via enhanced giucose-dependent insulin secretion in dipeptidyl peptidase Ⅳ-deficient Fischer rats.Biochem Biophys Res Commun 2001; 284(2):501-506.
  • [43]Zander M,Madsbad S,Madsen JL,Holst JJ.Effect of 6-week course of glucagon-like peptide Ⅰ on glycaemic control,insulin sensitivity,and beta-cell function in type 2 diabetes:a parallel-group study.Lancet 2002; 359(9309):824-830.
  • [44]Cornu M,Modi H,Kawamori D,Kulkarni RN,Joffraud M,Thorens B.Ghicagon-like peptide-1 increases beta-cell glucose competence and prohferation by translational induction of insulin-like growth factor-1 receptor expression.J Biol Chem 2010; 285(14):10538-10545.
  • [45]Vilsboll T,Zdravkovic M,Le-Thi T,Krarup T,Schmitz O,Courreges JP,Verhoeven R,Buganova I,Madsbad S.Liraglutide,a long-acting human glucagon-like peptide-1 analog,given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.Diabetes Care 2007; 30(6):1608-1610.
  • [46]Wei Y,Mojsov S.Tissue-specific expression of the human receptor for glucagon-like peptide-Ⅰ:brain,heart and pancreatic forms have the same deduced amino acid sequences,FEBS Lett 1995; 358(3):219-224.
  • [47]Goke R,Larsen PJ,Mikkelsen JD,Sheikh SP.Distribution of GLP-1 binding sites in the rat brain:evidence that exendin-4 is a ligand of brain GLP-1 binding sites.Eur J Neurosci 1995; 7(11):2294-2300.
  • [48]Perry TA,Greig NH.A new Alzbeimer's disease interventive strategy:GLP-1.Curr Drug Targets 2004; 5(6):565-571.
  • [49]During MJ,Cao L,Zuzga DS,Francis JS,Fitzsimons HL,Jiao X,Bland RJ,Klugmann M,Banks WA,Drucker DJ,Haile CN.Glucagon-like peptide-1 receptor is involved in learning and nenroprotection.Nat Med 2003; 9(9):1173-1179.
  • [50]Perry T,Haughey NJ,Mattson MP,Egan JM,Greig NH.Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.J Pharmacol Exp Ther 2002; 302(3):881-888.
  • [51]Perry T,Lahiri DK,Sambamurti K,Chen D,Mattson MP,Egan JM,Greig NH.Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide(Abeta)levels and protects hippocampal neurons from death induced by Abeta and iron.J Neurosci Res 2003; 72(5):603-612.
  • [52]Chalmers KA,Wilcock GK,Vinters HV,Perry EK,Perry R,Ballard CG,Love S.Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease.J Neurol 2009; 256(5):717-720.
  • [53]Craft S,Asthana S,Newcomer JW,Wilkinson CW,Matos IT,Baker LD,Cherrier M,Lofgreen C,Latendresse S,Petrova A,Plymate S,Raskind M,Grimwood K,Veith RC.Enhance-ment of memory in Alzheimer disease with insulin and somatostatin,but not glucose.Arch Gen Psychiatry 1999; 56(12):1135-1140.
  • [54]Rensink AA,Otte-Holler I,de Boer R,Bosch RR,ten Donkelaar HJ,de Waal RM,Verbeek MM,Kremer B.Insulin inhibits amyloid beta-induced cell death in cultured human brain pericytes.Neurobiol Aging 2004; 25(1):93-103.
  • [55]Lee CC,Kuo YM,Huang CC,Hsu KS.Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation.Neurobiol Aging 2009; 30(3):377-387.
  • [56]Dore S,Kar S,Zheng WH,Quirion R.Rediscovering good old friend IGF-Ⅰ in the new millenium:possible usefulness in Alzheimer's disease and stroke.Pharm Acta Helv 2000; 74(2-3):273-280.
  • [57]Qiu WQ,Folstein MF.Insulin,insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease:review and hypothesis.Neurobiol Aging 2006; 27(2):190-198.
  • [58]Gengler S,McClean PL,McCurtin R,Gault VA,H(o)lscher C.Val(8)GLP-I rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice.Neurobiol Aging 2010 Mar 30.[Epub ahead of print]doi:10.1016/j.neurobiolaging.2010.02.014
  • [59]Bandyopadhyay S,Huang X,Cho H,Greig NH,Youdim MB,Rogers JT.Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5'untranslated region,tolerance of SH-SY5Y and H4 neural cells to desferrioxamine,clioquinol,VK-28,and a piperazine chelator.J Neural Transm Suppl 2006;(71):237-247.
  • [60]Gilman CP,Perry T,Furukawa K,Grieg NH,Egan JM,Mattson MP.Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons.J Neurochem 2003; 87(5):1137-1144.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn